Literature DB >> 9512133

The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers.

K Fujiwara1, O Yokosuka, T Ehata, W L Chuang, F Imazeki, H Saisho, M Omata.   

Abstract

During the course of hepatitis B virus (HBV) infection, there exists a long period of normal liver function tests with different states of HBeAg/Ab. As the state of HBV in asymptomatic carriers was not well characterized, we quantitatively and qualitatively examined HBV in both HBeAg-positive and anti-HBe-positive asymptomatic carriers. Sera from 10 HBeAg-positive and 27 anti-HBe-positive asymptomatic carriers were analyzed. The amount of HBV DNA was determined by dot-blot hybridization and polymerase chain reaction. The mutations in precore and core regions, spanning 636 nucleotides, of hepatitis B virus were examined by directly sequencing the amplified HBV DNA. HBV DNA was detected in all 10 HBeAg-positive cases, whereas it was found in only 7 of 27 (26%) anti-HBe-positive cases by the nested PCR method. The mean amount of HBV DNA in HBeAg-positive cases was 10(9.1 +/- 0.7) copies/ml, while that in anti-HBe-positive cases was 10(1.0 +/- 1.5) copies/ml. There were no missense mutations in the entire precore and core genes of HBV DNA taken from HBeAg-positive asymptomatic carriers. In contrast, many mutations (mean 9.0 +/- 3.3, range 6-14) were detected in the core gene of seven anti-HBe-positive asymptomatic carriers including two cases with increments of the mutations. Analysis of the precore region revealed three wild-type and four mutant-type (including one coexisting with wild-type) cases. These data suggest that HBV exists in quite different ways in "asymptomatic" carriers; in the HBeAg-positive phase HBV probably coexists with the host and remains as the wild type, whereas in the anti-HBe-positive phase a drastically reduced amount of HBV with many mutations remains, probably as a consequence of the long-lasting interaction with the host. Nevertheless, such small amount of virus could cause fulminant hepatic failure. It is important to make further clinical and virological investigations in order to understand the state of asymptomatic carrier.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512133     DOI: 10.1023/a:1018870709286

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

1.  Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal.

Authors:  S P Tong; J S Li; L Vitvitski; C Trépo
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

2.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

3.  Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children.

Authors:  P I Lee; M H Chang; C Y Lee; H Y Hsu; J S Chen; P J Chen; D S Chen
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

4.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection.

Authors:  T Ehata; M Omata; O Yokosuka; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

5.  Discordance of hepatitis B e antigen/antibody and hepatitis B virus deoxyribonucleic acid in serum. Analysis of 1063 specimens.

Authors:  Y Matsuyama; M Omata; O Yokosuka; F Imazeki; Y Ito; K Okuda
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

6.  Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.

Authors:  S J Hadziyannis; H M Lieberman; G G Karvountzis; D A Shafritz
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

Review 7.  Hepatitis B virus immunopathogenesis.

Authors:  F V Chisari; C Ferrari
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

8.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

9.  Precore mutations and core clustering mutations in chronic hepatitis B virus infection.

Authors:  W L Chuang; M Omata; T Ehata; O Yokosuka; Y Ito; F Imazeki; S N Lu; W Y Chang; M Ohto
Journal:  Gastroenterology       Date:  1993-01       Impact factor: 22.682

10.  A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal.

Authors:  J P Villeneuve; M Desrochers; C Infante-Rivard; B Willems; G Raymond; M Bourcier; J Côté; G Richer
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

View more
  7 in total

1.  Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma.

Authors:  Y-H Ni; M-H Chang; H-Y Hsu; D-J Tsuei
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 2.  Current and future directions for treating hepatitis B virus infection.

Authors:  Akinobu Tawada; Tatsuo Kanda; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-06-18

3.  Naturally occurring core immune-escape and carboxy-terminal mutations\truncations in patients with e antigen negative chronic hepatitis B.

Authors:  Ranjit Chauhan; Shiv K Sarin; Manoj Kumar; Jayashree Bhattacharjee
Journal:  Hepatol Int       Date:  2011-12-02       Impact factor: 6.047

Review 4.  New perspective on the natural course of chronic HBV infection.

Authors:  Yong-Yuan Zhang; Ke-Qin Hu; Zhongping Duan
Journal:  Front Med       Date:  2014-05-29       Impact factor: 4.592

5.  Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India.

Authors:  Sanjeev Sharma; Balkrishan Sharma; Bhupesh Singla; Yogesh Kumar Chawla; Anuradha Chakraborti; Nitin Saini; Ajay Duseja; Ashim Das; Radha Krishan Dhiman
Journal:  Dig Dis Sci       Date:  2009-12-31       Impact factor: 3.199

6.  Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.

Authors:  Tatsuo Kanda; Masami Shinozaki; Hidehiro Kamezaki; Shuang Wu; Shingo Nakamoto; Makoto Arai; Keiichi Fujiwara; Nobuaki Goto; Fumio Imazeki; Osamu Yokosuka
Journal:  Int J Med Sci       Date:  2011-11-10       Impact factor: 3.738

7.  A study on fractional HBV model through singular and non-singular derivatives.

Authors:  Sunil Kumar; R P Chauhan; Ayman A Aly; Shaher Momani; Samir Hadid
Journal:  Eur Phys J Spec Top       Date:  2022-03-02       Impact factor: 2.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.